Nursing home placement in the Donepezil and Memantine in Moderate to Severe Alzheimer's Disease (DOMINO-AD) trial: secondary and post-hoc analyses
暂无分享,去创建一个
Robert Barber | Robert Howard | Craig Ritchie | Cornelius Katona | James Lindesay | Alistair Burns | Tony Johnson | Tom Dening | Bart Sheehan | Peter Bentham | Sube Banerjee | Jessica Adams | Roy W Jones | Robert Jones | J. Lindesay | T. Johnson | I. McKeith | C. Katona | C. Holmes | Sube Banerjee | A. Burns | T. Dening | Richard G. Brown | R. Barber | B. Sheehan | C. Ritchie | J. O’Brien | R. Howard | C. Ballard | M. Knapp | R. McShane | P. Bentham | E. Juszczak | Clive Holmes | Rupert McShane | Edmund Juszczak | Richard G Brown | Ashley Baldwin | D. Findlay | Robert Jones | Ajay Macharouthu | R. Hills | Jessica M. Adams | P. Phillips | Ian McKeith | Martin Knapp | Ashley Baldwin | Ajay Macharouthu | Clive Ballard | David Findlay | Roy Jones | John O'Brien | Robert Hills | Patrick P J Phillips | Richard G. Brown | Roy W Jones | Martin Knapp | Bart Sheehan | R. Howard | A. Baldwin
[1] Robert Gray,et al. A Proportional Hazards Model for the Subdistribution of a Competing Risk , 1999 .
[2] M Knapp,et al. Measurement of health-related quality of life for people with dementia: development of a new instrument (DEMQOL) and an evaluation of current methodology. , 2005, Health technology assessment.
[3] M Haupt,et al. [Clinical diagnosis of Alzheimer's disease]. , 1988, Deutsche medizinische Wochenschrift.
[4] J. Karlawish. Donepezil Delay to Nursing Home Placement Study is Flawed , 2004, Journal of the American Geriatrics Society.
[5] J. Becker,et al. Alteration of a Clinically Meaningful Outcome in the Natural History of Alzheimer's Disease by Cholinesterase Inhibition , 2005, Journal of the American Geriatrics Society.
[6] Swu-Jane Lin,et al. Predicting time to nursing home placement based on activities of daily living scores – a modelling analysis using data on Alzheimer's disease patients receiving rivastigmine or donepezil , 2009, Journal of medical economics.
[7] Martin Knapp,et al. Costing psychiatric interventions. , 1992 .
[8] S. Folstein,et al. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. , 1975, Journal of psychiatric research.
[9] J. Raftery,et al. Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial , 2004, The Lancet.
[10] D. Royall. Donepezil's Effects Remain Uncertain , 2004, Journal of The American Geriatrics Society.
[11] L. Schneider,et al. Long-term tacrine (Cognex) treatment , 1996, Neurology.
[12] D. King,et al. Scenarios of dementia care: what are the impacts on cost and quality of life? , 2014 .
[13] M. Folstein,et al. Clinical diagnosis of Alzheimer's disease , 1984, Neurology.
[14] S. Wisniewski,et al. Cholinesterase inhibitor treatment alters the natural history of Alzheimer's disease , 2002, Journal of neurology, neurosurgery, and psychiatry.
[15] T. Suzuki. Discontinuing donepezil or starting memantine for Alzheimer's disease. , 2012, The New England journal of medicine.
[16] M. Folstein,et al. Clinical diagnosis of Alzheimer's disease: Report of the NINCDS—ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease , 2011, Neurology.
[17] H. Lemij,et al. Surveillance for ocular hypertension: an evidence synthesis and economic evaluation. , 2012, Health technology assessment.
[18] M Jeffreys,et al. The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of Technology Appraisal No. 111): a systematic review and economic model. , 2012, Health technology assessment.
[19] Kristine Yaffe,et al. Patient and caregiver characteristics and nursing home placement in patients with dementia. , 2002, JAMA.
[20] J. Becker,et al. Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease , 2009, Journal of Neurology, Neurosurgery, and Psychiatry.
[21] B. Everitt,et al. Treatment with galantamine and time to nursing home placement in Alzheimer's disease patients with and without cerebrovascular disease , 2009, International journal of geriatric psychiatry.
[22] D. Geldmacher,et al. Donepezil Is Associated with Delayed Nursing Home Placement in Patients with Alzheimer's Disease , 2003, Journal of the American Geriatrics Society.
[23] R. Bucks,et al. Assessment of activities of daily living in dementia: development of the Bristol Activities of Daily Living Scale. , 1996, Age and ageing.
[24] Martin Knapp,et al. Donepezil and memantine for moderate-to-severe Alzheimer's disease. , 2012, The New England journal of medicine.
[25] Miguel A Hernán,et al. The hazards of hazard ratios. , 2010, Epidemiology.
[26] Paul C. Lambert,et al. Flexible Parametric Survival Analysis Using Stata: Beyond the Cox Model , 2011 .
[27] Patrick Royston,et al. Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcome , 2013, BMC Medical Research Methodology.
[28] Damian McEntegart,et al. The Pursuit of Balance Using Stratified and Dynamic Randomization Techniques: An Overview , 2003 .
[29] D. Molloy,et al. A Guide to the Standardized Mini-Mental State Examination , 1997, International Psychogeriatrics.
[30] D. Asch,et al. Caregivers’ preferences for the treatment of patients with Alzheimer’s disease , 2000, Neurology.
[31] T. Finucane. Another Advertisement for Donepezil , 2004, Journal of The American Geriatrics Society.
[32] Ming-Feng Hou,et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial , 2013, The Lancet.
[33] Roy W Jones,et al. DOMINO-AD protocol: donepezil and memantine in moderate to severe Alzheimer's disease – a multicentre RCT , 2009, Trials.